ClinicalTrials.gg
Active, not recruitingNCT06640049China AZUR-1Updated Nov 17, 2025

A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China

A Phase 2 interventional study of Dostarlimab in Neoplasms, Rectal, sponsored by GlaxoSmithKline. Active, not recruiting at 9 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 462 studies in Rectal Neoplasms with a site in China — 227 open to participants now, 266 under way, 42 of them phase 3. Rectal Neoplasms · China.

Enrollment
347th of 372
23 · median 100
Started
2024
with 47 others
Phase 2
155 of 462
95 open now
Primary completion
2027-10
later than 178 of 265 live
Registered
324th of 462
by date

Among the 462 studies in Rectal Neoplasms with a site in China, this one is the 347th largest by enrollment of the 372 interventional ones that give a count, is one of 48 that started in 2024, is one of 155 in phase 2, reaches primary completion later than 178 of the 265 other live ones, and was the 324th registered.

Rectal Neoplasms

2,403 studies on the registry are indexed under Rectal Neoplasms; 589 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

227 of the 462 studies in Rectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

222 more — sign in →

All 227 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 405 Rectal Neoplasms studies recruiting now, 210 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 462 studies in Rectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

The main goal of this study is to evaluate the effect of dostarlimab monotherapy in Chinese participants with locally advanced Mismatch-repair deficient (dMMR)/ Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment.

03

Conditions studied

  • Neoplasms, Rectal

Browse trials for

Keywords

  • Dostarlimab
  • GSK4057190A
  • TSR-042
  • Rectal cancer
  • dMMR
  • MSI-H
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has confirmed Stage II to III (T3-T4, N0, or T any, N+), locally advanced rectal adenocarcinoma
  • Participant has radiologically and endoscopically evaluable disease
  • Participant has a tumor which can be categorized as dMMR or MSI-H by central assessment

Exclusion criteria

Exclusion Criteria:

  • Participant has distant disease
  • Participant has received prior radiation therapy, systemic therapy, or surgery for management of rectal cancer
  • Has a known additional that progressed or required active treatment within the past 2 years
  • Has an active disease that has required systemic treatment in the past 2 years
  • Has experienced any of the following with prior immunotherapy: any irAE ≥ Grade 3, immune-related severe neurologic events of any-grade (e.g., myasthenic syndrome/myasthenia gravis, encephalitis, Guillain Barré Syndrome, or transverse myelitis), exfoliative dermatitis of any grade [SJS (Stevens-Johnson Syndrome, TEN (Toxic Epidermal Necrolysis), DRESS (Drug rash with eosinophilia and systemic symptoms)], or myocarditis of any grade. Non- laboratory abnormalities are not exclusionary
  • Has any history of interstitial lung disease or pneumonitis
  • Has received or plans to receive an organ or stem cell transplant that uses donor stem cells ( stem cell transplant)
  • Has a history of severe allergic and/or anaphylactic reactions to chimeric, human, or humanized antibodies, fusion proteins, or known allergies to dostarlimab, or its
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Dostarlimab monotherapy

    Participants will receive dostarlimab as monotherapy.

    Biological: Dostarlimab

Interventions

  • BiologicalDostarlimab

    Dostarlimab will be administered.

    Also known as: GSK4057190A, TSR-042

06

What researchers measure

Primary outcomes

  1. Number of Participants with Sustained Complete Clinical Response for 12 Months (cCR12) as assessed by Independent Central Review (ICR)

    cCR12 is achieved when a participant maintains complete clinical response (cCR) as assessed by Independent central review (ICR) for 12 months from the first disease assessment after last dose of study intervention. Timeframe calculation includes 6 months (9 cycles of dostarlimab, with each cycle lasting 21 days) plus an additional 12 months of assessment time, amounting to a total of 18 months.

    Time frame: 18 months

Secondary outcomes

  1. Number of Participants with Sustained Complete Clinical Response for 24 Months (cCR24) as assessed by ICR

    cCR24 is achieved when a participant maintains cCR as assessed by ICR for 24 months following their first disease assessment after last dose of study intervention. Timeframe calculation includes 6 months (9 cycles of dostarlimab, with each cycle lasting 21 days) plus an additional 24 months of assessment time, amounting to a total of 30 months.

    Time frame: 30 months

  2. Number of Participants with Sustained Complete Clinical Response for 36 Months (cCR36) as assessed by ICR

    cCR36 is achieved when a participant maintains cCR as assessed by ICR for 36 months following first disease assessment after last dose of study intervention. Timeframe calculation includes 6 months (9 cycles of dostarlimab, with each cycle lasting 21 days) plus an additional 36 months of assessment time, amounting to a total of 42 months.

    Time frame: 42 months

  3. Number of Participants with Event Free Survival at 3 years (EFS3) as assessed by Investigator

    EFS3 is defined as participants who remained alive and free of disease progression precluding surgery, local recurrence, and distant recurrence at 3 years from the first dose of study intervention as assessed by Investigator.

    Time frame: 3 years

  4. Event Free Survival (EFS) as assessed by Investigator

    EFS is defined as time from the date of first dose of study intervention to any of the following events including progression of disease that precludes surgery, local recurrence, distant recurrence (all as assessed by the investigator), or death due to any cause.

    Time frame: Up to approximately 77 months

  5. Number of Participants with cCR12 as assessed by Investigator

    cCR12 is achieved when a participant maintains cCR as assessed by Investigator for 12 months from the first disease assessment after last dose of study intervention. Timeframe calculation includes 6 months (9 cycles of dostarlimab, with each cycle lasting 21 days) plus an additional 12 months of assessment time, amounting to a total of 18 months.

    Time frame: 18 Months

  6. Number of Participants with cCR24 as assessed by Investigator

    cCR24 is achieved when a participant maintains cCR as assessed by Investigator for 24 months from the first disease assessment after last dose of study intervention. Timeframe calculation includes includes 6 months (9 cycles of dostarlimab, with each cycle lasting 21 days) plus an additional 24 months of assessment time, amounting to a total of 30 months.

    Time frame: 30 Months

  7. Number of Participants with cCR36 as assessed by Investigator

    cCR36 is achieved when a participant maintains cCR as assessed by Investigator for 36 months from the first disease assessment after last dose of study intervention. Timeframe calculation includes 6 months (9 cycles of dostarlimab, with each cycle lasting 21 days) plus an additional 36 months of assessment time, amounting to a total of 42 months.

    Time frame: 42 Months

  8. Objective Response Rate (ORR) assessed by ICR

    ORR is defined as number of participants achieving a partial response (PR), near complete response (nCR) or cCR at post-intervention disease assessment (PIDA) or at least 4 weeks but no longer than 8 weeks after PIDA for participants with nCR or incomplete clinical response (iCR) (PIDA 2) as assessed by ICR.

    Time frame: Up to 37 Weeks

  9. Objective Response Rate (ORR) as assessed by Investigator

    ORR by Investigator is defined as number of participants achieving a PR, nCR, or cCR at PIDA.

    Time frame: Up to 37 Weeks

  10. Organ Preservation Rate

    Organ Preservation Rate is defined as number of participants who did not undergo any rectal cancer surgery either as primary management or for local recurrence, or who did not have a permanent colostomy created, at any time up to 3 years.

    Time frame: Up to 3 years

  11. Disease-Specific Survival (DSS)

    DSS is defined as time from the date of first dose of study intervention to death due to disease under study.

    Time frame: Up to approximately 77 months

  12. Disease-Specific Response at 5 years (DSS5)

    DSS5 is defined as the number of participants not dying due to disease under study at 5 years from the first dose of study intervention.

    Time frame: Up to 5 years

  13. Overall Survival (OS)

    OS is defined as time from first dose of study intervention to death from any cause.

    Time frame: Up to approximately 77 months

  14. Overall Survival at 5 years (OS5)

    OS5 is defined as number of participants being alive at 5 years from first dose of study intervention.

    Time frame: Up to 5 years

  15. Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs), Immune related Adverse Events (irAEs) and AEs leading to death or discontinuation of study intervention.

    Time frame: Up to approximately 77 months

  16. Serum concentration of Dostarlimab

    Time frame: Up to approximately 77 months

  17. Concentration at the end of infusion (C-EOI) of Dostarlimab

    Time frame: Up to approximately 77 months

  18. Trough Concentration (C-trough) of Dostarlimab

    Time frame: Up to approximately 77 months

  19. Number of Participants with Anti-Drug Antibodies (ADA) against Dostarlimab

    Time frame: Up to approximately 77 months

07

Study locations

9 sites
  • GSK Investigational Site
    Chengdu, 610041, China
  • GSK Investigational Site
    Chongqing, 400010, China
  • GSK Investigational Site
    Guangzhou, 510060, China
  • GSK Investigational Site
    Guangzhou, 510655, China
  • GSK Investigational Site
    Hangzhou, 310016, China
  • GSK Investigational Site
    Hangzhou, China
  • GSK Investigational Site
    Jinan, 250117, China
  • GSK Investigational Site
    Kunming, 650106, China
  • GSK Investigational Site
    Shanghai, 200032, China
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2027, 36 months after the start.

Of 241 phase 2 interventional studies under Rectal Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 75. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2024
First posted
Oct 15, 2024
StartActual
Oct 17, 2024
Primary completionEst.
Oct 24, 2027
CompletionEst.
Apr 15, 2031
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06640049
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Oct 17, 2024
Primary completion
Oct 24, 2027 (estimated)
Completion
Apr 15, 2031 (estimated)
Last update
Nov 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dostarlimab

Start the discussion